Items where authors include "Cunningham, D"

Article

Muti, HS, Heij, LR, Keller, G et al. (32 more authors) (2021) Development and validation of deep learning classifiers to detect Epstein-Barr virus and microsatellite instability status in gastric cancer: a retrospective multicentre cohort study. The Lancet Digital Health, 3 (10). e654-e664. ISSN 2589-7500

Athauda, A, Nankivell, M, Langley, RE et al. (6 more authors) (2020) Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03). European Journal of Cancer, 137. pp. 45-56. ISSN 0959-8049

Rao, S, Sclafani, F, Eng, C et al. (18 more authors) (2020) International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. Journal of Clinical Oncology, 38 (22). pp. 2510-2518. ISSN 0732-183X

Davarzani, N, Hewitt, LC, Hale, MD et al. (8 more authors) (2020) Histological intratumoral heterogeneity in pretreatment esophageal cancer biopsies predicts survival benefit from neoadjuvant chemotherapy: results from the UK MRC OE02 trial. Diseases of the Esophagus, 33 (8). doaa058. ISSN 1120-8694

Pietrantonio, F, Miceli, R, Raimondi, A et al. (21 more authors) (2019) Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. Journal of Clinical Oncology, 37 (35). pp. 3392-3400. ISSN 0732-183X

Sundar, R, Ng, A, Zouridis, H et al. (18 more authors) (2019) DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial. European Journal of Cancer, 123. pp. 48-57. ISSN 0959-8049

Jones, RP, Psarelli, E-E, Jackson, R et al. (38 more authors) (2019) Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. JAMA Surgery, 154 (11). pp. 1038-1048. ISSN 2168-6254

Allum, WH, Smyth, EC, Blazeby, JM et al. (6 more authors) (2019) Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro‐oesophageal junction. British Journal of Surgery, 106 (9). pp. 1204-1215. ISSN 0007-1323

Smyth, EC, Rowley, S, Cafferty, FH et al. (17 more authors) (2019) Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial. JAMA Oncology, 5 (8). pp. 1181-1187. ISSN 2374-2437

Primrose, JN, Fox, RP, Palmer, DH et al. (26 more authors) (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. The Lancet Oncology, 20 (5). pp. 663-673. ISSN 1213-9432

Backen, AC, Lopes, A, Wasan, H et al. (16 more authors) (2018) Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. British Journal of Cancer, 119 (1). pp. 27-35. ISSN 0007-0920

Davarzani, N, Hutchins, GGA orcid.org/0000-0002-1707-4415, West, NP orcid.org/0000-0002-0346-6709 et al. (8 more authors) (2018) Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy – results from the MRC OE02 oesophageal cancer trial. Histopathology, 72 (7). pp. 1180-1188. ISSN 0309-0167

Hewitt, LC, Inam, IZ, Saito, Y et al. (12 more authors) (2018) Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study. European Journal of Cancer, 94. pp. 104-114. ISSN 0959-8049

Ghaneh, P, Hanson, R, Titman, A et al. (37 more authors) (2018) PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer. Health Technology Assessment, 22 (7). pp. 1-114. ISSN 1366-5278

Alderson, D, Cunningham, D, Nankivell, M et al. (14 more authors) (2017) Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet Oncology, 18 (9). pp. 1249-1260. ISSN 1470-2045

Battersby, NJ, Dattani, M, Rao, S et al. (17 more authors) (2017) A Rectal Cancer Feasibility Study with an Embedded Phase III Trial Design Assessing Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker to Stratify Management by Good And Poor Response to Chemoradiotherapy (TRIGGER): study protocol for a randomized controlled trial. Trials, 18. p. 394. ISSN 1745-6215

Davidson, M, Chau, I, Cunningham, D et al. (5 more authors) (2017) Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer. World Journal of Gastrointestinal Oncology, 9 (8). pp. 333-340. ISSN 1948-5204

Meyer, T, Fox, R, Ma, YT et al. (15 more authors) (2017) Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. The Lancet Gastroenterology & Hepatology, 2 (8). pp. 565-575. ISSN 2468-1253

Knowles, RL, Ridout, D, Crowe, S et al. (8 more authors) (2017) Ethnic and socioeconomic variation in incidence of congenital heart defects. Archives of Disease in Childhood, 102 (6). pp. 496-502. ISSN 0003-9888

Neoptolemos, JP, Palmer, DH, Ghaneh, P et al. (31 more authors) (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet, 389 (10073). pp. 1011-1024. ISSN 0140-6736

Glynne-Jones, R, Sebag-Montefiore, D, Meadows, HM et al. (9 more authors) (2017) Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. The Lancet Oncology, 18 (3). pp. 347-356. ISSN 1470-2045

Cunningham, D, Stenning, SP, Smyth, EC et al. (15 more authors) (2017) Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial. Lancet Oncology, 18 (3). pp. 357-370. ISSN 1470-2045

Hale, MD, Nankivell, M, Hutchins, GG et al. (11 more authors) (2016) Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma –results from the UK MRC OE02 trial. Oncotarget, 7 (47). pp. 77565-77575. ISSN 1949-2553

Smyth, E, Rowley, S, Allum, W et al. (17 more authors) (2016) A randomised phase II study of perioperative epirubicin, cisplatin and capecitabine (ECX) ± lapatinib for operable, HER-2 positive gastric, oesophagogastric junctional (OGJ) or lower oesophageal adenocarcinoma: Results from the UK MRC ST03 lapatinib feasibility study (ISRCTN 46020948). Annals of Oncology, 27 (suppl_6). LBA26. ISSN 0923-7534

Smyth, EC, Fassan, M, Cunningham, D et al. (13 more authors) (2016) Effect of pathologic tumor response and nodal status on survival in the medical research council adjuvant gastric infusional chemotherapy trial. Journal of Clinical Oncology, 34 (23). pp. 2721-2727. ISSN 0732-183X

Ghaneh, P, Wong, WL, Titman, A et al. (17 more authors) (2016) PET-PANC: Multi-centre prospective diagnostic accuracy and clinical value study of PET/CT in the diagnosis and management of pancreatic cancer. Pancreatology, 16 (3, S1). S1. S91-S91. ISSN 1424-3903

Obulkasim, A, Yistra, B, Van Essen, HF et al. (11 more authors) (2016) Reduced genomic tumor heterogeneity after neoadjuvat chemotherapy is related to favorable outcome in patients with esophageal adenocarcinoma. Oncotarget, 7 (28). pp. 44084-44095. ISSN 1949-2553

Crowe, S, Ridout, DA, Knowles, R et al. (9 more authors) (2016) Death and Emergency Readmission of Infants Discharged After Interventions for Congenital Heart Disease: A National Study of 7643 Infants to Inform Service Improvement. Journal of the American Heart Association, 5 (5).

Baird, R, Banks, I, Cameron, D et al. (53 more authors) (2016) An Association of Cancer Physicians’ strategy for improving services and outcomes for cancer patients. Ecancermedicalscience, 10. 608.

Sha, C, Barrans, S, Care, MA et al. (4 more authors) (2015) Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas. Genome Medicine: medicine in the post-genomic era, 7. 64. ISSN 1756-994X

Proceedings Paper

Athauda, A, Nankivell, MG, Langley, RE et al. (17 more authors) (2019) Impact of age and sex on chemotherapy (CTx) efficacy, toxicity and survival in early oesophagogastric (OG) cancer: A pooled analysis of 3265 patients from four large randomised trials (OE02, OE05, MAGIC & ST03). In: Journal of Clinical Oncology. Annual Meeting of the American Society of Clinical Oncology (ASCO), 31 May - 04 Jun 2019, Chicago, IL, USA. American Society of Clinical Oncology (ASCO) .

Hutchins, GGA orcid.org/0000-0002-1707-4415, Davarzani, N, West, NP orcid.org/0000-0002-0346-6709 et al. (8 more authors) (2018) Defining the Clinical Value of Pathological Lymph Node Status and Primary Tumour Regression Grading Following Neoadjuvant Therapy in Oesophageal Cancer: Results from the MRC OE02 Trial. In: Journal of Pathology. Maastricht Pathology 2018: 11th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, 19-22 Jun 2018, Maastricht, the Netherlands. Wiley , S16-S16.

Ghaneh, P, Wong, WL, Titman, A et al. (17 more authors) (2016) PET-PANC: Multi-centre prospective diagnostic accuracy and clinical value trial of FDG PET/CT in the diagnosis and management of suspected pancreatic cancer. In: JOURNAL OF CLINICAL ONCOLOGY. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 03-07 Jun 2016, Chicago, IL. American Society of Clinical Oncology .